Sulphonamide derivatives
US6303816A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 18, 1999 |
| Grant date | Oct 16, 2001 |
| Priority date | — |
| Expiry date | Oct 18, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula EQU R.sup.1 --L--NHSO.sub.2 R.sup.2 I in which PA1 R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic group; PA1 R.sup.2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R.sup.3 R.sup.4 N in which R.sup.3 and R.sup.4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and PA1 L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; PA1 and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula I, proce…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.